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Abstract: 
The Idiopathic Inflammatory Myopathies of childhood consist a heterogeneous group of 
autoimmune diseases characterised by proximal muscle weakness and pathognomonic skin 
rashes. The overall prognosis of juvenile myositis has improved significantly over recent 
years, but the long-term outcome differs substantially from patient to patient suggestive of 
distinct clinical phenotypes with variable responses to treatment. High doses of 
corticosteroids remain the cornerstone of therapy along with other immunosuppressant 
therapies depending on disease severity and response. The advent of biological drugs has 
revolutionised the management of various paediatric rheumatologic diseases, including 
inflammatory myopathies. There are few data from randomised controlled trials to guide 
management decisions, thus several algorithms for the treatment of juvenile myositis have 
been developed using international expert opinion. The general treatment goals now include 
elimination of active disease and normalization of physical function, so as to preserve normal 
growth and development, and to prevent long-term damage and deformities. This review 
summarizes the newer and possible future therapies of juvenile inflammatory myopathies, 
including evidence supporting their efficacy and safety.  
 
Key points: 
 Treatment of juvenile inflammatory myopathies mainly constitutes corticosteroids and 
methotrexate as a steroid-sparing agent, but must be tailored according to disease 
severity 
 Much of our knowledge on the use of DMARDS and biologic agents in JDM is based 
on anecdotal experience because of the lack of randomised control trials. 
  A multi-disciplinary approach to care by a team including a paediatric 
rheumatologist, a physiotherapist, an occupational therapist and a podiatrist is 
essential in order to achieve the best therapeutic outcome. 
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1.1 Introduction 
Idiopathic Inflammatory Myopathies (IIM) consist of an heterogeneous group of autoimmune 
diseases characterized by a chronic inflammatory process affecting muscles, skin and other 
organs [1]. Juvenile Dermatomyositis (JDM) is the most common IIM accounting for 
approximately 85% of cases [2, 3] while juvenile polymyositis (JPM) is seen in less than 5% 
of cases in most cohorts [2, 4].  Some patients with inflammatory myopathy may also 
demonstrate features of other autoimmune diseases including systemic lupus erythematosous 
(SLE), systemic sclerosis (SSc) and juvenile idiopathic arthritis (JIA). These patients are 
described as having overlap syndromes, and treatment should be personalised depending on 
the predominant features. 
Adult and juvenile myositis share characteristic clinical features such as the pathognomonic 
skin rashes and muscle inflammation but are both also highly heterogeneous, with distinct 
additional clinical features and distinct outcomes. Important clinical manifestations such as 
calcinosis, interstitial lung disease and malignancy differ substantially in prevalence between 
adult and juvenile myositis [5]. Children are more likely to develop calcinosis, vasculopathy 
and ulceration, despite which they still have a significantly better prognosis compared to 
adult cases which are more commonly complicated with malignancy and lung disease [6].  
Previously, the prognosis of JDM was poor with a reported mortality of 30% but also a 
significant percentage of disability [7]. With the advantage of recent therapeutic strategies 
and the development of new treatments, survival and outcomes have improved significantly 
with a reported mortality of <2% [8, 9]. As JDM is rare, much of our knowledge on treatment 
is based on anecdotal experience or small case series. In this review, we will discuss current 
therapeutic management, recent advances in the therapeutic strategies of JDM  and avenues 
for further research. 
1.2 Pathogenesis and the role of myositis specific antibodies 
The exact pathogenesis of JDM is not yet known. It is thought to be related to both humoral 
and cell -mediated mechanisms affecting small vessels and leading to vascular and muscle 
damage. Vasculopathy seems to play a central role in the pathogenesis of myositis and 
cutaneous involvement [10, 11], but is also central to other severe systemic features of the 
disease that contribute significantly to the burden of disease in children. The exact nature of 
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vasculopathy remains unclear but there is evidence of a true inflammatory small vessel 
vasculitis driven by interferons and other cytokines [11, 12] and a non-inflammatory 
occlusive vasculopathy with capillary drop out [13, 14]. Muscle biopsy shows not only 
immune cells infiltrates but also C5b–9 deposits. Since JDM is strongly associated with the 
presence of autoantibodies, it is presumed though yet not clearly demonstrated, that 
autoantibodies may activate complement triggering the release of pro-inflammatory 
cytokines, upregulation of adhesion molecules on endothelial cells, and migration of B and 
CD4+ T lymphocytes and plasmacytoid dendritic cells, into muscle tissue [15-17]. Type 1 
interferons produced by dendritic cells, in turn, stimulate the production of pro-inflammatory 
cytokines and enhance the expression or HLA class I and class II molecules [17]. 
The overall prognosis of JDM has improved significantly over recent years, but the long term 
outcome differs substantially from patient to patient [4, 18] suggestive of distinct clinical 
phenotypes. Predicting these different disease trajectories has been challenging. In recent 
years, IIM can be defined into more homogeneous subsets as there is now increasing 
evidence to support a critical association between genotype, serotype and clinical phenotype 
in adult and juvenile inflammatory myopathies [19-21]. Myositis specific antibodies (MSA) 
and myositis associated antibodies (MAA) in IIMs are present in 60% of cases [6]. They have 
different prevalence and associations across the myositis spectrum depending on the age of 
disease onset. In some cases the antibody levels may reflect disease activity. Certain 
myositis-specific antibodies and their  associated clinical phenotype remain unchanged across 
different age  groups; for example,  anti-PM-Scl with scleroderma overlap features,  anti-Mi-
2 with classic skin rash of dermatomyositis, and antihistidyl RNA synthetase (Jo-1) with  
interstitial lung disease [6], though the latter is rare in childhood.  Other associations differ: 
anti-TIF1-gamma (p155/140) is found in 23–29% of patients with JDM and is associated 
with an increased risk of cutaneous disease and a prolonged course [22] while in adult DM is 
found in 13-21% and is strongly associated with the development of malignancy [5]. Anti-
NXP2 (p140) is present in 11-23% and is  associated with the development of calcinosis in 
children with JDM [23] , in an age dependent fashion, in contrast with adults where it is 
found in only 1.6% of cases [5].  It is not known whether particular antibodies predate the 
specific features with which they are associated: they could be useful as prognostic 
biomarkers. In support of this, a recent study demonstrated that the MSA status in 
combination with the muscle biopsy score can be a significant prognostic tool [24]. 
1.3 Clinical manifestations 
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The inflammatory myopathies are characterized by symmetric, proximal muscle weakness 
which is present in 95% patients at the time of diagnosis [25]. This may present with 
functional limitations, such as difficulty getting up from the floor, getting in and out of motor 
vehicles, climbing stairs, or lifting the head up when lying flat on a bed. In JDM patients 
pathognomonic skin rashes are typically present consisting mainly of Gottron’s papules and 
heliotrope rash.  These cutaneous abnormalities are apparent in approximately three-quarters 
of patients presenting with JDM [26]. Cutaneous manifestations may precede or follow the 
onset of muscle involvement by months or even several years, and may be the most active or 
difficult feature of the IIM to manage [27]. Nailfold capillary changes are present in most of 
the patients at the time of diagnosis [28]. Arthritis is another common manifestation of JDM 
with a reported prevalence of 23-64% of cases. It may occur early in the disease course and is 
usually non-erosive [29].  Small vessel vasculitis is a characteristic feature of that group of 
diseases and thought to be related with the severe extramuscular manifestations of the disease 
such as intestinal ischaemia and perforation, interstitial lung disease, skin ulceration and 
development of calcinosis. Pulmonary manifestations are much less common in children with 
JDM than adults, but interstitial lung disease may occur. Subclinical systolic and diastolic 
dysfunction has been demonstrated in patients with JDM [30, 31], while pericarditis has also 
been reported [32].  Lipodystrophy has been reported in a number of JDM patients and 
usually occurs years after disease onset and is often associated with other metabolic 
abnormalities [33]. 
1.4       Diagnosis of Juvenile Dermatomyositis 
Diagnosis of JDM is based on Peter and Bohan Criteria published in 1975 [10]. Diagnostic 
criteria include characteristic cutaneous changes, proximal muscle weakness, elevated muscle 
enzymes, electromyography (EMG) demonstrating denervation and muscle biopsy displaying 
necrosis and inflammation. The diagnosis of JDM is probable if rash is present plus two of 
the other four criteria are present and definite in the presence of rash and three out of the 
other four criteria. In an international survey of paediatric rheumatologists published in 2006, 
clinical manifestations (proximal muscle weakness and characteristic skin rash) and 
laboratory findings (muscle enzymes) were routinely used in the diagnosis of JDM, while 
magnetic resonance (MRI) was also deemed important and used by 60% of responders to 
detect inflammatory muscular changes [34]. Muscle biopsy and EMG were used only by 
61.3% and 55.5% [34], respectively, suggesting for the first time that a number of children 
would fail to meet the current diagnostic criteria necessary for the inclusion in research and 
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other collaborative studies. That necessitates the revision of current criteria. An international 
effort is currently ongoing to agree and validate new classification criteria.  
 
International consensus discussions for treatment pathways 
In rare diseases, such as JDM, international collaboration is necessary to facilitate research, 
better understand the pathogenesis and develop new therapeutic strategies. To accommodate 
international collaboration, a number of core sets of variables have been developed to be used 
in the clinical trials for quantification of response and clinical improvement [35, 36]. Despite 
being used in clinical trials, these core sets have not been completely adopted into clinical 
practice, as they require significant clinical time to be performed. Recently, a big effort has 
been underway for the development of an internationally accepted minimal core dataset 
which is very important for monitoring of disease status in each patient, development of 
standards of care, assessment of quality care, and as potential end points in clinical trials [37].  
As there are few data from randomised controlled trials to guide management decisions in the 
children with IIM, recently several algorithms for the treatment of moderately severe JDM 
were developed using international expert opinion [38-40]. The Childhood Arthritis and 
Rheumatology Research Alliance (CARRA) has described several treatment strategies for 
initial therapy for JDM based upon a North American survey of practice [39], while recently  
consensus-based recommendations for the management of JDM were published by a 
European initiative called Single Hub and Access point for paediatric Rheumatology in 
Europe (SHARE) [40] to optimise and disseminate diagnostic and management regimens in 
Europe for children and young adults with rheumatic diseases. 
1.5 Current Therapeutic options 
The aim of drug therapy in patients with JDM is to induce and maintain a complete remission 
of all symptoms, and thus to allow a child to achieve normal growth, development, and allow 
full participation in school, career, sport and all other aspects of normal life. While most 
children do very well overall with this condition, quality of life can be significantly affected, 
often as a consequence of associated complications, which can result in pain and disruption 
of daily tasks and activities. Early pharmacological and non-pharmacological treatment of the 
disease is imperative for the prevention of irreversible soft tissue and organ damage. The 
intensity of initial therapy differs according to the increasing severity of the symptoms [41], 
which range from mild disease to serious, life-threatening weakness with internal organ 
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damage, ulcerative skin lesions and development of extensive calcinosis. Pharmacological 
interventions for JDM include glucocorticoids (GCs), disease-modifying drugs (DMARDs) 
and biologics. Non-pharmacological interventions, such as physiotherapy interventions (e.g. 
therapeutic exercises, massage), podiatrist and occupational therapist input when required, 
may help patients maintain their functional status while also contributing to maintenance of 
an increase in bone mineral density, and ultimately to the prevention of osteopenia. This 
combined multi-disciplinary approach to care is essential for overall better management of 
symptoms and leads to better ultimate outcomes. 
1.5.1 Corticosteroids 
The prognosis of JDM has significantly improved over the last decades with the use of 
steroids as first line treatment. Early aggressive treatment is reported to improve the long-
term outcome [42]. Corticosteroids act quickly to stop the disease process.  Different 
corticosteroid regimes have been proposed for the initial treatment of JDM with the most 
reported used being oral prednisolone in a dose of 2 mg/kg/day and pulses with intravenous 
methylprednisolone (IV MP) 30mg/kg/day followed by oral prednisolone. A comparative 
study [43] failed to demonstrate superiority of one regime over the other in the 3-year 
outcome scores although more severe cases were always treated with IV MP, while other 
reports [44-46], suggested that residual weakness, relapsing disease and calcinosis are lower 
in patients receiving pulse intravenous rather than oral therapy. Moreover, a study published 
in 2000 [47] suggested that IV MP although more costly, is cost effective when compared to 
oral corticosteroids. In the presence of dysphagia, gastrointestinal symptoms or more severe 
disease, IV MP is generally used as there is reported reduced absorption of oral prednisolone, 
especially when gastrointestinal vasculopathy is suspected [48]. Many specialist centres now 
prefer the use of IV MP pulses for 3-5 days followed by a 2mg/kg/day dose of prednisolone 
(or IV MP equivalent) and  the subsequent oral steroid dose to be given as a single morning 
dose, as this regimen has less effects on the hypothalamic-pituitary-adrenal function and 
growth, even in young children [49]. According to the response, the daily dose of steroid 
treatment is then tapered. Low dose of steroids may be needed long term especially in some 
types of IMM (for example, anti-SRP Ab positive- myositis [50], as complete discontinuation 
may precipitate a disease flare.  
The significant anti-inflammatory effects of corticosteroids cannot however be separated 
from their metabolic effects. Children are more vulnerable to steroid side effects than adults, 
particularly the effects on growth, immunity and adrenal suppression. Corticosteroid 
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treatment is connected to significant side effects, including growth retardation, Cushingoid 
appearance, hypertension, secondary glucose intolerance/ diabetes cataract osteoporosis, and 
vertebral fractures. Moreover, apart from the physical side effects, steroid therapy has been 
associated with adverse psychological side effects, ranging from psychotic symptoms to mild 
changes in mood and cognition [51]. Early introduction of steroid sparing agents may allow 
faster weaning of steroid treatment.  
1.5.2 Disease-modifying antirheumatic drugs (DMARDS) 
1.5.2.1 Methotrexate (MTX) 
Methotrexate (MTX) has been the first-line conventional DMARD with marked efficacy in 
JDM for over 30 years. Despite the recent advances in pharmacotherapy, MTX remains an 
important cornerstone of therapy for JDM and is used extensively both as mono- and 
combination therapy worldwide. Until recently, most of the knowledge about MTX use in 
JDM was mainly based on case reports and small cohorts [52-56]. The only randomised 
controlled trial (RCT) comparing prednisone alone vs combination of prednisone with either 
MTX or Ciclosporin recently demonstrated that the combination of steroids and MTX had the 
best outcome regarding efficacy and safety [57]. A large retrospective study on treatment 
practise in Europe and South America involving 490 children with IIM demonstrated a 50% 
use of MTX in these regions [58].  In general, for children with JDM, MTX therapy is started 
at a dose of 15-20 mg/m2/week, and given by the subcutaneous route [40]. Around 70% of 
patients with JDM benefit significantly from MTX therapy, with the maximum therapeutic 
effect usually becoming apparent 3 months after the beginning of treatment [57]. Treatment 
with MTX is usually continued for one year after remission is achieved.   
MTX administration has been related with gastrointestinal side effects, including oral 
ulceration, nausea, vomiting, abdominal pain and diarrhoea with a reported prevalence 
ranging between 10 to 50% in different cohorts of Juvenile Idiopathic Arthritis patients [59-
61], 62,63] Anticipatory and associative gastrointestinal adverse effects experienced before 
MTX administration are also common [62, 63]. Fewer data are available on how common 
these gastrointestinal side effects are for children with JDM taking MTX. Serious side effects 
such as bone marrow suppression and hepatotoxicity (as demonstrated by elevated liver 
enzymes) are less frequently reported and usually transient once MTX dose is omitted [64]. It 
is important to highlight that in children with active JDM it may be difficult to distinguish 
MTX related hepatopathy against elevation of muscle isoenzymes of transaminases. The 
9 
 
concomitant use of folic or folinic acid has been suggested to try to prevent the development 
of these side effects [65]. Blood tests for monitoring of full blood count, liver and renal 
function are recommended while on MTX treatment with the optimal frequency of testing yet 
to be established [64].  
1.5.2.2 Ciclosporin  
Ciclosporin has also been used in many centres as a steroid-sparing agent. The use of 
ciclosporin was mainly based on findings of efficiency in series of cases [66-68]. The RCT 
discussed above comparing isolated glucocorticosteroids and its association with 
methotrexate or ciclosporin suggested that combination treatment with prednisone plus either 
ciclosporin or methotrexate was superior to prednisone monotherapy in patients with JDM, at 
6 months and after at least 24 months of treatment [57].  Of note ciclosporin is more 
commonly used in Europe than in North America centres.  
Ciclosporin is usually given in divided doses 3-5mg/kg/day. It necessitates monitoring during 
the first few months to ensure its trough serum level is optimal (90-150mg/mL)Furthermore, 
ciclosporin is toxic to many organs, i.e.: the kidneys, liver and bone marrow [69]. 
Consequently, renal tests should be closely monitored; when creatinine levels increase more 
than 30%, cyclosporine should be discontinued. Cases of posterior reversible encephalopathy 
syndrome (PRES) have been reported in patients treated with ciclosporin with increasing risk 
when combined with steroid treatment [70, 71]. In current practice, because ciclosporin use is 
difficult, this drug may be reserved for patients who have failed to respond adequately to 
steroids, other immunosuppressive agents and intravenous immunoglobulins. 
1.5.2.3 Mycophenolate Mofetil (MMF) 
Mycophenolate mofetil (MMF) is emerging as a promising drug, especially when used in 
refractory IIM [69] and in patients with interstitial lung disease (ILD) refractory to 
steroids[72].  Two retrospective studies where 12 [73] and 50 [74] JDM patients were treated 
with MMF demonstrated a good response and safety profile. It is usually given at starting 
dose of 600mg/m2/day, then can be increased to 1200mg/m2/day divided in two doses if well 
tolerated. Side effects include gastrointestinal intolerance (diarrhoea), leukopenia, kidney and 
liver toxicity [75]. Response to MMF is expected within 2–3 months.  
1.5.2.4 Azathioprine 
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Azathioprine has been used as an alternative to MTX in children with refractory JDM [54]. 
Most of the knowledge on azathioprine comes from the experience in adult patients [76]. It is 
usually given at an initial dose of 1mg/kg/day for two weeks and then increased to 
2mg/kg/day according to thiopurine-methyl-transferase enzyme activity. Bone marrow 
suppression and elevated liver enzymes are the commonest side effects [75] and routine 
blood monitoring is also recommended. In our practise, azathioprine may be used if 
methotrexate is not tolerated and in some cases with persistent mild skin disease in 
conjunction with MTX with good results (unpublished data). 
1.5.2.5 Cyclophosphamide (CyC) 
Cyclophosphamide has been used as a third line therapeutic agent [77]. It is reserved for 
IMM patients refractory to most other therapies and/or for cases complicated with severe 
pulmonary involvement, ulcerative skin disease or gastrointestinal vasculopathy. Several case 
studies demonstrate the efficacy of treatment with CyC in both paediatric and adult patients 
with IIMs [72, 77]. It is usually given at a dose of 500-1000 mg/m2 (usually to a maximum 
dose of 1.2gr) monthly for 6 doses [77]. Main side effects include alopecia, haemorrhagic 
cystitis, sterility, teratogenicity and increased risk of infection and malignancy [72]. Close 
monitoring of blood tests is suggested to decide about further dosing. In boys of reproductive 
age, sperm banking should be advised while in girls of reproductive age the use of a 
gonadotropin-releasing hormone agonist for ovarian protection should be thought [78]. It is 
important though to highlight that there may be limitations in the use of the above mentioned 
fertility preservation options including severe or life threatening cases, when CyC needs to be 
given urgently and cost barriers, particular to each country and local regulations. A recent 
analysis of a large cohort of JDM patients treated with CyC indicated efficacy and low rates 
of adverse events [79]. 
1.5.2.6 Hydroxychloroquine (HCQ) 
Hydroxychloroquine is an antimalarial agent commonly used in the treatment of 
rheumatologic diseases. Data on the use of HCQ in JDM is limited, primarily based on 
anecdotal experience and two small, retrospective reviews [80, 81]. HCQ is mainly used in 
milder cases for skin rashes. The usual dose of hydroxychloroquine in children is 3‐5 mg/kg 
kg/day divided 1‐2 times per day with a maximum of 400mg per day. Hydroxychloroquine is 
generally considered to be a very safe medication. The most concerning side effect is ocular 
toxicity for which yearly ophthalmological examinations are recommended [82].  
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1.5.2.7 Tacrolimus 
Tacrolimus binds the immunophilin FKBP12, inhibits calcineurin, and suppresses T 
lymphocytes secreting cytokines, such as interleukin-2. Small case series have reported the 
use of tacrolimus in children with refractory JDM, skin disease, global disease activity and 
physical function were reported to improve. Patients were able to reduce corticosteroid 
therapy, and the medication was well tolerated [83, 84]. 
1.5.2.8 Intravenous immunoglobulins (IVIG) 
Intravenous immunoglobulins (IVIG) is recommended in IIM patients refractory to steroids 
and methotrexate. IVIG has been used in the treatment of JDM since the 1980s as reported in 
case reports and small case series. The majority of reported patients experienced 
improvement in skin disease and muscle strength, and the use of IVIG also reduced the 
cumulative glucocorticoid dose in most patients [85-88]. In 2011 a large retrospective study 
including 78 JDM patients confirmed the efficacy of IVIG in controlling JDM disease 
activity, particularly for steroid resistant patients [89]. Both the Childhood Arthritis and 
Rheumatology Research Alliance (CARRA) and SHARE proposed the use of IVIG in 
refractory JDM once conventional treatment with steroids and methotrexate has failed [,38, 
40]. IVIG is usually given as a dose of 2 g/kg (maximum dose 70 g), administered as a single 
dose or divided over two days. Two different regimes have been proposed [89-91]. IVIG is 
either given every two weeks, initially for three doses, and is then generally administered 
monthly for up to two years or it is given in monthly infusions starting from the first dose. At 
present there is no robust evidence for superiority of one or other of these regimes. The 
decision to begin IVIG typically occurs when patients experience persistent or increasing 
symptoms as glucocorticoids are weaned, indicating steroid resistance or steroid dependence. 
However, IVIG is often used earlier in very severe cases of JDM. 
Most of the adverse effects associated with IVIG administration are mild and transient. The 
immediate AEs include headache, flushing, malaise, chest tightness, fever, chills, myalgia, 
fatigue, dyspnoea, back pain, nausea, vomiting, diarrhoea, blood pressure changes, 
tachycardia, and anaphylactic reactions, especially in IgA-deficient patients. Severe 
anaphylactoid or anaphylactic reactions are more likely to occur in patients with severe IgA 
deficiency (< 1.2 mg/dl) and those with anti-IgA antibodies of the IgE type [92, 93]. 
Complete absence of IgA has been recently shown to be a significant risk factor for the 
development of anaphylactic reactions [94]. The IgA content of the different IVIG 
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preparations varies and  also plays a significant role in the development of severe 
anaphylactic reactions in the high risk patients [95]. However, using a IVIG preparation with 
low IgA concentration does not preclude that the infusion will be reaction free and up to date 
there have been no studies to support the evidence that increasing levels of IgA in the 
different IVIG preparations relate with increasing numbers of side effects.   Late AEs are rare 
and include acute renal failure, thromboembolic events, aseptic meningitis, neutropenia, and 
autoimmune haemolytic anaemia, skin reactions, and rare events of arthritis. Immediate AEs 
can be treated by the slowing or temporary discontinuation of the infusion and symptomatic 
therapy with analgesics, non-steroidal anti-inflammatory drugs, antihistamines, and 
glucocorticoids in more severe reactions [96]. 
1.6 Biologic agents 
Biologic agents are genetically engineered drugs designed to target specific areas of the 
immune system and selectively block inflammatory pathways implicated in disease processes 
[97]. They include monoclonal antibodies, soluble cytokine receptors and recombinant 
receptor antagonists [98]. There are several reports of the safety and efficacy of biologics in a 
range of other inflammatory conditions [97, 99]. Outcomes such as elimination of any pain 
and inflammation, normalization of short-term and long-term function and achievement of 
normal growth, physical and psychosocial development are now realistic priorities for 
clinicians and patients. On the other hand, biologic therapies while demonstrating significant 
efficacy, have also been linked to rare but severe adverse events such as lymphoma, serious 
infections, demyelination and hepatotoxicity [100, 101]. All biological agents are available 
either as a subcutaneous injection or should be administered intravenously, complicating their 
use in the paediatric population [97]. In addition, the evidence for many of the treatments 
used in paediatric rheumatology  is incomplete and currently all biologic therapies are off-
label in the indication of JDM. We herein discuss current evidence for the biologic agents  
used in juvenile IIM (Table 1). 
1.6.1 Targeting B cells 
1.6.1.1 Rituximab (RTX) 
Rituximab is a chimeric monoclonal antibody directed against the human CD20 receptor, 
which is present only on B cells. Until recently, the effectiveness of rituximab was suggested 
by case reports and case series in adult and pediatric patients with refractory disease [102, 
103]. A randomized trial (that included 152 adults with myositis as well as 48 children with 
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JDM), demonstrated that most patients eventually had some benefit, although the time that it 
took to show improvement was long and there was no statistically significant difference 
between subjects who received rituximab early or after a delay of nine weeks[104]. 
Interestingly, in a follow-up sub-analysis of the Rituximab in Myositis trial, JDM cases a 
quicker initial improvement and a better outcome when compared to adult [105].There is an 
increasing interest about the place of rituximab in the treatment of anti-SRP myositis with a 
recent report suggesting an improvement in muscle strength and/or decline in CK levels as 
early as two months after rituximab treatment in adult cases [106].  
Current UK practice regarding dosing of rituximab consists of two doses 750 mg/m2 two 
weeks apart [107]. Pre-dosing with 100mg IV methylprednisolone, chlorphenamine and 
paracetamol an hour before the infusion is recommended to prevent the mild side effects that 
occur during or up to 24 hours after receiving rituximab and include mild throat tightening, 
flu-like symptoms, rash, itchiness, dizziness and back pain. Severe allergic reactions have 
been reported [103]. Infections have been reported in some patients with prolonged 
hypogammaglobulinemia while late-onset neutropenia might also occur after RTX and may 
result in serious infections [108]. Thus, monitoring of white cell count should be performed 
in the event of fever or infection after treatment with Rituximab [108]. 
1.6.1.2 Anti-Tumour Necrosis Factor (TNF) agents  
The two modalities used for TNF inhibition involve soluble receptors (Etanercept) and 
antibodies (Infliximab, Adalimumab, Golimumab, and Certolizumab). There is currently only 
limited formal evidence for the use of Adalimumab and Infliximab in paediatric cases of 
IIMs.  
1.6.1.2.1 Infliximab and Adalimimab 
Infliximab is a chimeric human-murine IgG1 monoclonal antibody produced in murine 
hybridoma cells by recombinant DNA technology. It was marketed first for treatment of 
rheumatoid arthritis in the late 90s.  The rationale for using anti-TNF treatment in myositis is 
the up-regulation of TNFα and its receptor in muscle tissue of these patients and also the 
expression of this cytokine in the endothelium of subjects with DM [109]. In 2008, a case 
series reported effect of Infliximab in children with refractory JDM and development of 
calcinosis [110]. Evaluation of 66 patients with JDM, recruited from the UK JDM Cohort and 
Biomarker Study and actively treated with anti-TNF agents, both Infliximab and 
Adalimumab showed significant improvements in muscle and skin involvement, as well as in 
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overall disease activity. There were also significant improvements in skin involvement 
assessed using the modified skin Disease Activity Score [111]. Paradoxically, there have 
been cases of adults with inflammatory myopathies where Infliximab induced an increase in 
type I IFN serum activity resulting not only in no clinical improvement but even in disease 
exacerbation [112]. Moreover, a recent review reported 20 patients who developed 
dermatomyositis and polymyositis after receiving anti-TNF treatment for other autoimmune 
diseases [113]. This could be the result of the cross-regulation between TNFa and type I IFN, 
which is known to play a significant role into the pathogenesis of the inflammatory 
myopathies [114].  
Infliximab is given as an infusion at a dose of 6mg/kg every 2 weeks for the first three doses 
followed by monthly doses. Severe adverse reactions include anaphylactic reactions, while 
mild to moderate adverse reactions include infection [115, 116]. Adalimumab is a sc injection 
given at a dose of 24mg/m2 fortnightly, up to a maximum dose of 40mg. The most common 
side effect of Adalimumab is localized reaction at the injection site while increased risk of 
infection and specifically tuberculosis is a well recorded adverse effect [117].   
1.6.1.3 Other biologic agents 
There are few reports coming from adults reporting the use of other biologic agents in adults 
with DM/PM. A recently published review of current pharmacological treatment of idiopathic 
inflammatory myopathies [69] described three cases of refractory myositis treated with 
tocilizumab with promising results [118-120] and three case reports showing beneficial 
effects of co-stimulation blockade using Abatacept in myositis [121-123]. A randomized 
clinical trial is underway to test this hypothesis (ClinicalTrials.gov Identifier: 
NCT02594735). 
. 
1.7 Adjunctive therapies 
Adjunctive therapy includes a number of pharmacological and non-pharmacological therapies 
which contribute significantly to a better long-term outcome and prevent complications 
related to the disease process but also to the medications used. JDM rash is known to be a 
photosensitive rash and sun exposure is known to exacerbate disease flares. It is thus 
recommended the daily use of high factor sun sunscreen [40]. Concomitant use of calcium 
and vitamin D supplements is recommended to prevent osteoporosis, as long term high doses 
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of corticosteroids are usually required for the treatment of IIMs [124, 125]. Moreover, a large 
systematic review and meta-analysis demonstrated that corticosteroid use is associated with 
increased risk of gastrointestinal bleeding and perforation [126]. Thus, it is suggested the use 
of gastroprotective drugs for as long as the patient is on corticosteroid treatment. 
Physical and occupational therapy are important adjunctive measures to pharmacologic 
therapy. Children with IIMs are usually hypoactive leading to deconditioning and reduction 
in functional ability. Even when disease is well controlled, they still experience significant 
fatigue [127] and anaerobic- and aerobic exercise intolerance [128]. Moreover, decreased 
physical activity is known to be related with complications associated with a sedentary 
lifestyle including cardiovascular disease and obesity. Several studies have demonstrated the 
benefit of a specialized physiotherapy program in increasing muscle strength and improving 
muscle endurance [129, 130]. 
1.8 Future treatment options 
1.8.1 JAK inhibitors 
 A number of agents have been used in one to a few patients with refractory disease who have 
failed other immunosuppressive therapies. It is now increasingly recognised that JDM falls 
into the category of diseases driven by interferons collectively referred to as 
“interferonopathies” [131, 132]. Excessive interferon expression may drive endothelial injury 
ultimately leading to poor outcomes in JDM. Patients with evidence of ongoing endothelial 
injury may therefore benefit from janus kinase (JAK) inhibition, which acts directly 
downstream of interferon activation [133]. JAK inhibitors have been successfully used in 
other interferonopathies, notably the proteasome associated auto-inflammatory syndromes 
that clinically and immunologically share similar features with JDM [133]. A compassionate 
use program for JAK inhibition has already begun in North America for severe refractory 
JDM and we have now recruited the first refractory case of JDM in our institute. We predict 
that JDM patients with persistent endothelial injury could be ideal candidates to stratify for 
this new treatment. 
1.9 Conclusions  
Despite recent therapeutic advances, the treatment of juvenile myositides remains 
challenging. Current practise is mainly based on anecdotal experience and only recently 
consensus treatment protocols have been developed for the standardisation of treatment as a 
result of international efforts. Disease rarity and heterogeneity is the main obstacle in 
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conducting clinical trials. Corticosteroids remain the first line treatment followed by steroid 
sparing agents. In refractory cases, IVIG can be added, while in regards to biologic agents 
knowledge comes mainly from case series with the exception of rituximab.  
Cyclophosphamide is emerging as a third line agent in more severe or refractory cases but 
toxicity should not be dismissed. Although, the overall prognosis of JDM has significantly 
improved over the recent years, a number of children with JDM still suffer significant 
complications and have a poor outcome highlighting the heterogeneity of the disease and the 
need of better understanding its pathophysiology. Vasculopathy is central to the severe extra-
muscular manifestations of the disease, thus understanding the nature of vasculopathy and 
monitoring overtime may give insight to new therapeutic modalities such as JAK inhibitors 
and anti-complement agents. In conclusion, the use of targeted personalised treatment has 
been elucidated as the way forward.  
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  Table 1. Biologic agents currently used in Juvenile Myositis 
Medication Mode of 
action 
Administration Doses 
Abatacept Humanised 
selective  
T-cell co-
stimulatory 
modulator 
IV infusion over 
30 min. 
10mg/kg at 0,2,4 
weeks, then every 4 
weeks, max dose 1gr 
Adalimumab Humanized 
soluble anti-
TNF 
monoclonal 
antibody  
SC 24mg/m2 up to 40 
every 2 weeks 
Infliximab Chimeric 
human-murine 
anti-TNF IgG1 
monoclonal  
antibody  
IV infusion 6 mg/kg at 0, 2, 6 
weeks,                               
then every 4-8 weeks 
according to response 
Rituximab Chimeric anti-
CD20 
monoclonal 
antibody 
IV infusion 750mg/m2 on day 0-14 
(given with 100mg 
methylprednisolone 
and often 
cyclophosphamide) 
Tocilizumab Humanised 
recombinant 
anti-IL-6 
receptor 
monoclonal 
antibody 
IV infusion  ≥30 kg:             8 
mg/kg once every 
2 weeks, 
 BW <30 kg:   12 
mg/kg once every 
27 
 
2 weeks,  
BW, body weight; IV, intravenous; IL, interleukin; SC, subcutaneous; TNF, 
Tumour Necrosis Factor. 
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